2021-12-10 Meeting notes

Public Page

Date

Dec 10, 2021

ANTITRUST STATEMENT

As participants in this meeting, we need to be mindful of the constraints of antitrust laws. There shall be no discussions of agreements or concerted actions that may restrain competition. This prohibition includes the exchange of information concerning individual prices, rates, coverages, market practices, claims settlement practices, or any other competitive aspect of an individual company’s operation. Each participant is obligated to speak up immediately for the purpose of preventing any discussion falling outside these bounds.

Agenda

Budget
Financial Statement REview

Meeting Minutes

Nov 2021 Financial Statement
- Revenue New: Difficult to forecast, particularly during COVID where there has been lower activity with new startups, etc.
- Revenue Renewal: Variance is driven by two factors
  - AMFAM has said they want to cancel, which is a $15k impact
  - New billing system functions differently and the timing of invoices is different that may create a temporary change in billing cadence. It will self-correct over time as new invoices are generated out of the new system.
  - 3 large company payments are outstanding, but are in process as we work with their procurement departments on PO’s and Invoicing processes.
- Expenses are in line with the exception of Executive Bonus which was paid in 2021 for a 2020 expense.
  - This will be more evident once the 2021 bonus check is issued in December
2022 Budget
- Reduced renewal revenue by $15k to reflect AMFAM cancellation
- Increased Executive travel
- Increased Proj Mgr travel

Up Next

Antitrust Agreement and Meeting minutes acceptance

Action items

Decisions

Participants

@Paul Barry @Kim DeVallance Caron @Steve Betley (Unlicensed) @Ashley.Denison @Phil Martinez @Greg Best

Finance Committee